Table 1.
Patient characteristics
| Characteristics | Value |
|---|---|
| Age, years | |
| Mean (SD) | 66.5 (8.0) |
| Median | 67.8 |
| Range | 47.1–82.8 |
| PSA at time of PET/CT, ng/mL | |
| Mean (SD) | 36.2 (86.3) |
| Median | 19.2 |
| Range | 4.9–745.7 |
| Clinical T stage, n (%) | |
| T1 | 36 (47.4) |
| T2 | 17 (22.4) |
| T3 | 22 (28.9) |
| T4 | 1 (1.3) |
| Clinical N stage, n (%) | |
| N0 | 57 (75.0) |
| N1 | 12 (15.8) |
| Nx | 7 (9.2) |
| Gleason score, n (%) | |
| 6 | 3 (3.9) |
| 7 | 11 (14.5) |
| 8 | 30 (39.5) |
| 9 | 31 (40.8) |
| 10 | 1 (1.3) |
| Proportion of positive cores on biopsy, % (NA=1) | |
| Mean (SD) | 62.1 (28.7) |
| Median | 61.9 |
| Range | 3.3–100.0 |
| ADT at time of the PET/CT, n (%) (NA=4) | |
| Yes | 9 (11.8) |
| No | 63 (82.9) |
| Treatment (+/− ADT), n (%) (NA=3) | |
| RP | 27 (35.5) |
| EBRT | 35 (46.1) |
| EBRT + chemotherapy | 5 (6.6) |
| Chemotherapy | 4 (5.3) |
| Others | 2 (2.6) |
| Pathological T stage, n (%) | |
| T2 | 6 (22.2) |
| T3 | 21 (77.8) |
ADT: androgen-deprivation therapy; EBRT: external beam radiation therapy; NA: not available; PET/CT: positron-emission tomography-computed tomography; PSA: prostate-specific antigen; RP: radical prostatectomy; SD: standard deviation.